Minesse 60/15 micrograms FC tablets.
PDF Leaflet Revision Date: 10 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of pregnancy.
Dosage (summary)
One active tablet daily for 24 days, followed by 4 days of inactive tablets.
Special Populations
- Elderly
- Postpartum women
Pregnancy & Breastfeeding
Not indicated in pregnancy; may affect lactation.
Key Drug Interactions
- Antiviral HCV medicines
- Rifampicin
- St. John's wort
Contraindications
- Hypersensitivity to components
- History of thromboembolism
- Uncontrolled hypertension
- Known or suspected pregnancy
Common side effects
- Headache
- Nausea
- Mood changes
- Breakthrough bleeding
Counselling Points
- Use nonhormonal backup for first 7 days if starting late
- Does not protect against STIs
- Report mood changes or severe headaches
Serious warnings
- Increased risk of thromboembolism
- Cigarette smoking increases cardiovascular risks
- Monitor blood pressure
Important Disclaimer
The Minesse 60/15 micrograms FC tablets. professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
